Phenformin is an antidiabetic drug from the biguanide class. It was marketed as DBI by Ciba-Geigy, but was withdrawn from most markets in the late 1970s due to a high risk of lactic acidosis, which was fatal in 50% of cases. Phenformin was developed in 19 + some more technical info; chemically it is a phenethyl-substituted biguanide that is more lipophilic than metformin and thus shows different tissue distribution and mitochondrial interactions. Its primary pharmacologic action is reduction of hepatic gluconeogenesis and enhancement of peripheral glucose uptake, effects linked to inhibition of mitochondrial respiratory complex I and downstream effects on cellular energy sensing pathways. Phenformin has greater mitochondrial accumulation and a longer apparent elimination profile than metformin, factors that contributed to its safety issues. Analytical characterization typically employs HPLC for assay and impurity profiling, with confirmatory mass spectrometry and NMR used for structural identification of related substances.
Typical quality limits applied to phenformin substance are an assay specification of 98.0 to 102.0 percent by HPLC, water content not more than 0.5 percent by Karl Fischer, and heavy metals below 10 ppm. Related substances and degradation products commonly monitored include other biguanide-type impurities such as buformin and metformin residues if present from synthesis cross-contamination, guanylurea and dicyandiamide-derived fragments from hydrolysis, and low levels of phenethylamine-related synthetic intermediates. Typical impurity acceptance criteria used for control are individual related substances not more than 0.2 percent and total impurities not more than 1.0 percent, with any identified or suspected genotoxic impurity controlled below 0.03 percent in line with ICH principles. Residual solvents are limited according to ICH Q3C class limits and are controlled analytically by GC, while identity and purity are confirmed by retention time, MS fragmentation pattern, and, where needed, NMR.
Phenformin was used to lower blood glucose in type 2 diabetes by reducing hepatic glucose production and improving peripheral glucose uptake.
Metformin and phenformin are both biguanides, but phenformin is more lipophilic and accumulates in mitochondria to a greater extent, which contributed to a higher risk of lactic acidosis; metformin has a safer clinical profile and is the biguanide retained for routine use.
Phenformin inhibits mitochondrial respiratory complex I more strongly than metformin, impairing oxidative phosphorylation and increasing anaerobic metabolism and lactate production; combined with reduced lactate clearance in susceptible patients this can lead to lactic acidosis.
Phenformin has been marketed under the trade name DBI by Ciba-Geigy and is also referred to as phenethylbiguanide in descriptive chemical terms.
